Trial Profile
Effects of Dapagliflozin on 24-h Glycemic Changes in Japanese Patients with type 2 Diabetes Mellitus (T2DM), who Receives Basal supported Oral Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2022
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DBOT
- 13 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 28 Oct 2016 Planned End Date changed from 30 Jun 2017 to 31 Jul 2017.
- 28 Oct 2016 Status changed from not yet recruiting to recruiting.